Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons

Current Rheumatology Reports

Volumn 10, Issue 1, 2008, Pages 67-73

  Muscal, Eyal ^b   Brey, Robin L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 6; LA ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; ORAL CONTRACEPTIVE AGENT; PADGEM PROTEIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; WARFARIN; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHOREA; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; GUILLAIN BARRE SYNDROME; HEMOLYTIC ANEMIA; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; LIVEDO RETICULARIS; MATERNAL MORBIDITY; MENTAL DISEASE; MIGRAINE; MORTALITY; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARESTHESIA; PATHOGENESIS; PREGNANCY; PREVALENCE; RECURRENT DISEASE; REVIEW; SEIZURE; SPINAL CORD DISEASE; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; VALVULAR HEART DISEASE; VASCULAR DISEASE; BLOOD; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; STROKE; VENOUS THROMBOEMBOLISM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 44949098326     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0012-y     Document Type: Review

References (48)

1. Bertolaccini ML, Khamashta MA, Hughes GR: Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005, 1:40-46.
2. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002, 346:752-63.
3. Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006, 4:295-306.
4. Pierangelli SS, Chen PP, González EB: Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006, 13:366-375.
5. Hanly JG: Antiphospholipid syndrome: an overview. CMAJ 2003, 168:1675-1682.
6. Lim W, Crowther MA, Eikelboom JW: Management of the antiphospholipid antibody syndrome: a systemic review. JAMA 2006, 295:1050-1057.
7. Kamat AV, D'Cruz DP, Hunt BJ, et al.: Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica 2006, 91:1674-1680.
8. Lockshin MD, Erkan D: Treatment of the antiphospholipid syndrome. N Engl J Med 2003, 349:1177-1179.
9. Cervera R, Khamashta MA, Font J, et al.: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003, 82:299-308.
10. Merrill JT, Asherson RA: Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2006, 2:81-89.
11. Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardization committee of the ISTH. Thromb Haemost 1995, 74:1185-1190.
12. Galli M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2005, 101:1827-1832.
13. Pierangelli SS, Vega-Ostertag ME, Harris EN: Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells a pathway to targeted therapies. Thromb Res 2004, 114:467-476.
14. Salmon JE, Girardi G, Holers VM: Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002, 61:46-50.
15. Dignat-George F, Camoin-Jau L, Sabatier F, et al.: Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004, 91:667-673.
16. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.: Toll-like receptor and antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
17. Hulstein JJ, Lenting PJ, de Laat B, et al.: Beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007, 110:1483-1491.
18. Meroni PL, Tincani A, Sepp N, et al.: Endothelium and the brain in CNS lupus. Lupus 2003, 12:919-928.
19. Abbott NJ, Mendonca LL, Dolman DE: The blood-brain barrier in systemic lupus erythematosus. Lupus 2003, 12:908-915.
20. Connor P, Hunt BJ: Cerebral haemostasis and antiphospholipid antibodies. Lupus 2003, 12:929-934.
21. Trysberg E, Nylen K, Rosengren LE. et al.: Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003, 48:2881-2887.
22. Caronti B, Calderaro C, Alessandri C, et al.: Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998, 11:425-429.
23. Chapman J, Cohen-Armon M, Shoenfeld Y, et al.: Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
24. Riccio A, Andreassi C, Eboli M: Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-D-aspartate receptors. Neurosci Lett 1998, 257:116-118.
25. Ziporen L, Shoenfeld Y, Levy Y, et al.: Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies: a mouse model. J Clin Invest 1997, 100:613-619.
26. Sanna G, Bertolaccini ML, Cuadrado MJ, et al.: Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003, 42:200-213.
27. Brey RL: Management of the neurological manifestations of APS-what do the trials tell us? Thromb Res 2004, 114:489-499.
28. Janhardan V, Wolf PA, Kase CS, et al.: Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attacks: the Framingham cohort and offspring study. Stroke 2004, 35:736-741.
29. Menon S, Jameson-Shortall E, Newman SP, et al.: A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999, 42:735-741.
30. McLaurin E, Holliday SL, Williams P, Brey RL: Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005, 64:297-303.
31. Jacobson MW, Rapport LJ, Keenan PA, et al.: Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol 1999, 21:251-264.
32. Buller HR, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126(3 Suppl):401S-428S.
33. Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303-308.
34. Khamashta MA, Cudardo MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995, 332:993-997.
35. Crowther MA, Ginsberg JS, Julian J, et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138.
36. Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848-853.
37. The APASS Writing Committee: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
38. Toloza SM, Uribe AG, McGwin G, et al.: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947-3957.
39. Akimoto T: Risk factors for recurrent thrombosis: Prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 2005, 56:601-609.
40. Roldan CA, Gelgand EA, Qualls CR, et al.: Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005, 95:1441-1447.
41. Krause I, Lev S, Fraser A, et al.: Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005, 64:1490-1493.
42. Alarcon-Segovia D, Boffa MC, Branch W, et al.: Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003, 12:499-503.
43. Erkan D, Harrison MJ, Levy R, et al.: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007, 56:2382-2391.
44. Chapman J, Rand JH, Brey RL, et al.: Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003, 12:514-517.
45. Angelini L, Ravelli A, Caporali R, et al.: High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 1994, 94:500-503.
46. Lanthier S, Kirkham FJ, Mitchell LG, et al.: Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children. Neurology 2004, 62:194-200.
47. Berkun Y, Padeh S, Barash J, et al.: Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006, 55:850-855.
48. Roubey RA: New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials and tribulations. Arthritis Rheum 2003, 48:3004-3008.